Close Menu

siRNA

Alnylam Pharmaceuticals said this week that it and collaborators have developed a novel class of lipid nanoparticles capable of greater target inhibition than the company's existing lipid delivery agents.

By Doug Macron
About a year and a half after its founding, siRNA delivery firm Qualiber has secured a $30,000 low-interest loan from the North Carolina Biotechnology Center to help it with non-scientific startup activities.

Alnylam Pharmaceuticals announced this week that it has added ALN-APC, an siRNA-based treatment for hemophilia, to its formal drug-development pipeline.

The technology is 100 times more potent that the company's current research-only transfection reagent, according to a Life Tech official.

The partnership will specifically include STP601, Sirnaomics' preclinical treatment for ocular neovascularization diseases, in the Greater China and Southeast Asian markets.

The kinase, LMTK3, regulates estrogen receptor α, which is key to patient response to endocrine therapies like tamoxifen. A study of 613 breast cancer samples linked high LMTK3 expression levels to significantly shorter disease-free survival and overall survival.

The deal represents an expansion of an ongoing partnership between Cenix and Janssen focused on improving in vivo siRNA-based target validation methodologies in the central nervous system.

Pages

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.